Emerging therapies for inv(16) AML
Sridevi Surapally, Daniel G. Tenen, John Anto Pulikkan
Abstract
The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-SMMHC-driven leukemogenesis and recent advances in therapeutic approaches to target CBFβ-SMMHC in inv(16) AML.
Topics & Concepts
MedicineIntensive care medicineCancer researchAcute Myeloid Leukemia ResearchProtein Degradation and InhibitorsHistone Deacetylase Inhibitors Research